Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:AXSM NASDAQ:IRON NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$76.50+2.1%$63.70$12.44▼$77.90$10.71B1.282.61 million shs340,978 shsAXSMAxsome Therapeutics$224.89+0.8%$171.73$96.09▼$234.29$11.54B0.59700,853 shs94,457 shsIRONDisc Medicine$67.76+0.3%$64.91$40.00▼$99.50$2.59B0.93604,913 shs53,701 shsPRAXPraxis Precision Medicines$330.78-0.8%$318.06$35.18▼$356.00$9.22B2.76458,806 shs96,249 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+0.16%+6.81%+22.78%+10.09%+435.98%AXSMAxsome Therapeutics+8.00%+20.57%+32.37%+20.22%+91.48%IRONDisc Medicine+1.02%+0.49%+3.70%-17.22%+39.07%PRAXPraxis Precision Medicines+2.81%+3.54%+7.38%+9.88%+755.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$76.50+2.1%$63.70$12.44▼$77.90$10.71B1.282.61 million shs340,978 shsAXSMAxsome Therapeutics$224.89+0.8%$171.73$96.09▼$234.29$11.54B0.59700,853 shs94,457 shsIRONDisc Medicine$67.76+0.3%$64.91$40.00▼$99.50$2.59B0.93604,913 shs53,701 shsPRAXPraxis Precision Medicines$330.78-0.8%$318.06$35.18▼$356.00$9.22B2.76458,806 shs96,249 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+0.16%+6.81%+22.78%+10.09%+435.98%AXSMAxsome Therapeutics+8.00%+20.57%+32.37%+20.22%+91.48%IRONDisc Medicine+1.02%+0.49%+3.70%-17.22%+39.07%PRAXPraxis Precision Medicines+2.81%+3.54%+7.38%+9.88%+755.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.83Moderate Buy$84.2010.06% UpsideAXSMAxsome Therapeutics 2.90Moderate Buy$251.2611.73% UpsideIRONDisc Medicine 2.75Moderate Buy$104.8054.66% UpsidePRAXPraxis Precision Medicines 3.00Buy$590.7878.60% UpsideCurrent Analyst Ratings BreakdownLatest IRON, ARWR, AXSM, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.005/5/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$217.00 ➝ $242.005/5/2026AXSMAxsome Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$228.00 ➝ $310.005/5/2026AXSMAxsome Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$241.00 ➝ $246.005/4/2026AXSMAxsome Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/4/2026AXSMAxsome Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$245.00 ➝ $260.005/1/2026ARWRArrowhead Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$88.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M12.92$0.12 per share639.78$3.64 per share21.02AXSMAxsome Therapeutics$638.50M18.12N/AN/A$1.75 per share128.51IRONDisc MedicineN/AN/AN/AN/A$19.52 per shareN/APRAXPraxis Precision Medicines$8.55M1,078.21N/AN/A$34.85 per share9.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M$1.5350.00N/AN/A18.54%35.64%13.61%5/7/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.69N/A40.30N/A-26.59%-246.90%-29.04%N/AIRONDisc Medicine-$212.18M-$5.99N/AN/AN/AN/A-32.80%-30.19%5/7/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.46N/AN/AN/AN/A-58.74%-53.54%5/7/2026 (Estimated)Latest IRON, ARWR, AXSM, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.1068N/AN/AN/A$73.84 millionN/A5/7/2026Q1 2026IRONDisc Medicine-$1.6227-$1.65-$0.0273-$1.65$0.44 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58N/AN/AN/A$0.10 millionN/A5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million2/26/2026Q4 2025IRONDisc Medicine-$1.69-$1.62+$0.07-$1.62$0.15 million($19.88) million2/23/2026Q4 2025AXSMAxsome Therapeutics-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.293.383.38AXSMAxsome Therapeutics1.381.551.48IRONDisc Medicine0.0421.9421.94PRAXPraxis Precision MedicinesN/A10.2210.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%AXSMAxsome Therapeutics81.49%IRONDisc Medicine83.70%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%AXSMAxsome Therapeutics20.60%IRONDisc Medicine3.64%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.03 million134.99 millionOptionableAXSMAxsome Therapeutics38051.44 million40.84 millionOptionableIRONDisc Medicine3038.16 million36.77 millionNot OptionablePRAXPraxis Precision Medicines11027.87 million27.10 millionOptionableIRON, ARWR, AXSM, and PRAX HeadlinesRecent News About These CompaniesPraxis Precision Medicines, Inc. $PRAX Shares Bought by Vanguard Group Inc.3 hours ago | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5 at 4:01 PM | globenewswire.comPraxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor ConferenceMay 4 at 4:01 PM | globenewswire.comPraxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge?May 3 at 7:08 PM | finance.yahoo.comA Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder ReturnsMay 3 at 7:08 PM | finance.yahoo.comOptimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for UlixacaltamideApril 29, 2026 | finance.yahoo.comMoody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAXApril 29, 2026 | marketbeat.comPictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAXApril 29, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)April 27, 2026 | theglobeandmail.comPraxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in NeurologyApril 27, 2026 | insidermonkey.comM&T Bank Corp Purchases Shares of 12,586 Praxis Precision Medicines, Inc. $PRAXApril 27, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in Praxis Precision Medicines, Inc. $PRAXApril 27, 2026 | marketbeat.comPraxis Precision Medicines (PRAX) Gets a Buy from LifeSci CapitalApril 24, 2026 | theglobeandmail.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Buy" by BrokeragesApril 24, 2026 | marketbeat.comPraxis Precision Medicines (PRAX) Projected to Post Earnings on FridayApril 24, 2026 | marketbeat.comPraxis Precision Medicines (PRAX): One of the Best Upside StocksApril 23, 2026 | insidermonkey.com5 Best Upside Stocks to Buy According to AnalystsApril 23, 2026 | insidermonkey.comFDA Moves Ulixacaltamide Forward As Praxis Valuation Gap Draws FocusApril 21, 2026 | finance.yahoo.comMassachusetts Financial Services Co. MA Purchases New Shares in Praxis Precision Medicines, Inc. $PRAXApril 18, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1% - Time to Sell?April 16, 2026 | marketbeat.comWhy Praxis, a top 1% biotech, just surged into a bullish breakoutApril 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 2026Alcoa Dips After Q1 Miss, But Higher Aluminum Prices LoomBy Thomas Hughes | April 18, 2026Rust to Riches: The Great Resource Realignment By Jeffrey Neal Johnson | April 9, 2026IRON, ARWR, AXSM, and PRAX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$76.50 +1.57 (+2.10%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Axsome Therapeutics NASDAQ:AXSM$224.89 +1.83 (+0.82%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Disc Medicine NASDAQ:IRON$67.76 +0.17 (+0.25%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$330.78 -2.53 (-0.76%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
